Inserm Transfert is a legally incorporated subsidiary of Inserm, the French National Institute of Health and Medical Research. Technology transfer and life sciences knowledge. Intellectual property. Innovation valorisation. Start ups creation. Filiale privée de l’Inserm. Transfert de technologies et de connaissances en sciences de la vie. Propriété intellectuelle. Valorisation de l’innovation. Création d’entreprise.France
http://www.inserm-transfert.fr/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
4.2 seconds
16x16
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
83
SITE IP
213.186.33.2
LOAD TIME
4.215 sec
SCORE
6.2
Home | inserm-transfert.fr Reviews
https://inserm-transfert.fr
Inserm Transfert is a legally incorporated subsidiary of Inserm, the French National Institute of Health and Medical Research. Technology transfer and life sciences knowledge. Intellectual property. Innovation valorisation. Start ups creation. Filiale privée de l’Inserm. Transfert de technologies et de connaissances en sciences de la vie. Propriété intellectuelle. Valorisation de l’innovation. Création d’entreprise.France
inserm-transfert.fr
Projects engineering - Inserm Transfert
https://www.inserm-transfert.fr/en/industry-projects-engineering.html
Maturation, Protecting and IP. Partnering: R&D, Public health. Growing research funding opportunities for companies are offered by supra-national institutions such as the European Commission or charitable foundations. With the aim of increasing the success of scientists from SME or biotech start-ups and facilitating international innovation and technology cooperation, we have developed unique expertise. In designing, leveraging appropriate funding, managing and completing. Maturation, Protecting and IP.
How we work - Inserm Transfert
https://www.inserm-transfert.fr/index.php/how-we-work
Maturation, Protecting and IP. Partnering: R&D, Public health. Inserm Transfert carries out knowledge transfer operations on behalf of Inserm to develop, protect and exploit the results and know-how generated by its researchers and. Inserm / C.Demerens. Match them with industry needs. Help with securing maturation funding. (see link). Help with implementing R&D or licensing agreements (see link). Guidance for designing, setting up and negociating your Public health project. (see link). 33 (0)1 55 03 01 00.
Home - Inserm Transfert
https://www.inserm-transfert.fr/index.php
TargEDys and Inserm Transfert. On behalf of Rouen Normandy University and Rouen University Hospital (CHU) sign an exclusive international licensing agreement on a patent portfolio in microbiome-based research. SAS, an immuno-oncology diagnostic company, Inserm. Its subsidiary, today announced the commercialization of Immunoscore Colon, a unique diagnostic assay for guiding therapeutic decisions in colon cancer. Maturation, Protecting and IP. Partnering: R&D, Public health. Maturation, Protecting and IP.
Events - Inserm Transfert
https://www.inserm-transfert.fr/en/events.html
Maturation, Protecting and IP. Partnering: R&D, Public health. Page 1 of 2. July 4-5th - The Corum Conference Centre, Montpellier - France. The 4th Antibody Industrial Symposium 2016 (AIS2016). Meeting offers an ideal conference for scientists, industries, physicians and policy makers to exchange about Therapeutic Antibodies. The Scientific committee has set-up an exciting program focusing on the following theme: Current and Next Generation Antibody Formats. The topics covered during this meeting are:.
R&D, Licensing - Inserm Transfert
https://www.inserm-transfert.fr/en/partnering/rad.html
Maturation, Protecting and IP. Partnering: R&D, Public health. Partnering: R&D, Public health. R&D contracts (MAT, CDA,.). Inserm Transfert's primary objective in licensing technology or signing R&D partnerships is to maximize the likelihood that technologies and know-how will reach the market in a timely fashion. We place great value on building strong public-private partnerships between biopharmaceutical companies and academic research teams/centres to accomplish this strategic goal. How do we do it?
TOTAL PAGES IN THIS WEBSITE
19
NEWS AND EVENTS
http://www.myasterix.eu/en/news-and-events
A collaborative research project. Update on Myasterix study: Safety report summary. The Myasterix Phase 1b study (EudraCT 2015-002880-41) is followed by a Data Review Committee which conducted a formal safety data review in August and then in December 2016. The second data review also shows that the preliminary immunogenicity results and comparison of the 2 injection levels (Low Dose and High Dose) suggest that the High Dose has a greater immunogenic potential than the Low Dose. The High Dose level i...
MYASTERIX ACTIVITIES
http://www.myasterix.eu/en/myasterix-activities
A collaborative research project. MG) is a neuromuscular disorder. In which functional acetylcholine receptors (AChR) become depleted at neuromuscular junctions due to an antibody-mediated autoimmune attack on the neuromuscular synapse. AChR antibodies can be detected in the serum of 90% of patients with generalised MG. It is a rare orphan disease. With a prevalence of 1.6 2 per 10,000 people and an incidence of 1.2 1.5 per 100,000 people in the EU. Current treatments include symptomatic pharmacotherapy.
Pratical Informations | COHORT
http://www.cohortinnovationday.com/pratical-informations
Download the access map. ARIIS (Alliance for Research and Innovation in Health Industries) and Aviesan (Alliance for Life Sciences and Health) are pleased to invite you to. THE SECOND MEETING OF THE COHORT INNOVATION DAY (CID 2016). From 9 am to 18 pm. Les Salons de l’Aveyron. 17 Rue de l’Aubrac. With the support of Inserm Transfert. Premier Forum Franco-Québécois d’Innovation en Santé les 11 et 12 octobre 2016. 7ème édition des Rencontres Internationales de Recherche le 3 novembre 2016.
2013 FAID - About the Organizers
http://www.faid2013.france-science.org/about_inserm.html
Founded in 2000, InsermTransfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). Inserm Transfert also manages European and International research projects, supports large scale projects in epidemiology and public health. A 397m life sciences seed investment company. About Inserm Transfert Initiative. Photo credits from top to bottom:.
Rare 2015 - Les maladies rares : Quelles attentes et quels enjeux pour la société ?
http://www.rare2015.com/index.php
PRà SENTATIONS INTERVENANTS 2015. Laquo; Les maladies rares : quelles attentes et quels enjeux pour la société? Christian DELEUZE, Président - Genzyme SAS and Polyclonals. Pr Didier LACOMBE, Fédération Française de Génétique Humaine. Tel : 04 67 64 01 75. Tel : 01 44 64 14 77. Ils témoignent sur RARE 2013. Suivez RARE 2015 sur les rà seaux sociaux :. 03 Mars 2015 : Ouverture des inscriptions. 17 Mars 2015: Ouverture de la soumission des posters. Avec le soutien de.
Consortium Overview | ens@t-ht
http://www.ensat-ht.eu/consortium
Ens@t-ht is a collaborative research project funded in part through the EU's Horizon 2020 research and innovation programme. Find out here who is involved and how the project is managed by the executive committee and other boards. The Consortium and the Partners. ExCom meeting November 2016. First ENS@T-HT consortium meeting in April. Improving treatment of hypertension: ENS@T-HT EU project launch. Latest news from ens@t-ht. ExCom meeting November 2016. First ENS@T-HT consortium meeting in April.
pharmactuposition.blogspot.com
Industrie Pharmaceutique: février 2012
http://pharmactuposition.blogspot.com/2012_02_01_archive.html
Blog et nouvelles sur Automédication, biotechnologies médicales, emploi, statistiques, dispositifs médicaux, matériel médical,statistiques. Moteur de Recherche dans l'Industrie Pharmaceutique [websites sélectionnés]. GlaxoSmithKline (GSK), partenaire d’Inserm Transfe. TOP 10 des labos de l’automédication en 2011 [baro. PwC « Diagnostics 2011 : l’intérêt pour le sect. Mardi 14 février 2012. GlaxoSmithKline (GSK), partenaire d’Inserm Transfert Initiative [Investissements d’avenir]. 20 janvier 2012 - GSK.
Eyevensys
http://www.eyevensys.com/pages/17-investors.html
The Eyevensys Breakthrough Technology. Eyevensys was incepted late 2008, but it was only in January 2012 that it completed an initial seed financing of EUR 1.6 million. As of June 2015 the Company has raised 8,1 M , and has further secured additional funds from investors and public sources to fully support through its Phase I clinical program. Boehringer Ingelheim Venture Fund. Founded in 2000, InsermTransfert SA is the private subsidiary of the French National Institute of Health and Medical Research (I...
TOTAL LINKS TO THIS WEBSITE
83
inserlenzier's blog - Blog de inserlenzier - Skyrock.com
C mn log c fait pr les choco et belle gooooo de ba bie. 14/06/2010 at 6:40 AM. 12/12/2010 at 7:08 AM. Subscribe to my blog! Don't forget that insults, racism, etc. are forbidden by Skyrock's 'General Terms of Use' and that you can be identified by your IP address (66.160.134.2) if someone makes a complaint. Please enter the sequence of characters in the field below. Posted on Sunday, 12 December 2010 at 7:08 AM. Please enter the sequence of characters in the field below. Don't forget that insults, racism...
Inserleval ETT - Trabajo temporal
Inserleval ETT - Trabajo temporal. Tiene su origen como tal en 1997, es una realidad empresarial presente, a través de sus proyectos, en diferentes sectores de actividad. Su trayectoria empresarial es el resultado de una estrategia basada en la diversificación de la actividad. Nos carateriza la honestidad, integridad, responsabilidad social y civismo en todas las lineas de negocio. INSERLEVAL ETT - AGENCIA DE COLOCACION AUT.1000000121. 14/05/2014 INSERLEVAL ETT, SE CONVIERTE EN. leer más. SE PRECISA JARD...
广西内联网络系统有限责任公司
Institut national de la santé et de la recherche médicale
Forces de la recherche. Neurosciences, sciences cognitives, neurologie, psychiatrie. Rêves de recherche, rêve de chercheurs. Les acteurs de la recherche sur le cancer. Recherche sur les cancers : tout s’accélère (web documentaire). Rêves de recherche, rêve de chercheurs. Immunologie, inflammation, infectiologie et microbiologie. Enjeux scientifiques et médicaux. Rêves de recherche, rêve de chercheurs. Physiopathologie, métabolisme, nutrition. Rêves de recherche, rêve de chercheurs. Faire un don ou un legs.
Home
Working with a company. A response dedicated to your requirements. Our strategic innovation domains. Working with a company. A response dedicated to your requirements. Our strategic innovation domains. Welcome to the new Inserm Transfert website. Inserm Transfert, your partner for value creation and technology transfer. Inserm Transfert, specialised in technology transfer and life sciences, was founded in 2000. Are you a company? February 06, 2018. November 23, 2017. L’Inserm, Inserm Transfert et la SATT...
Unité U674
Présentation de l'unité U674. Genetic alterations of liver tumors. Présentation de l'unité U674.
Home page
You are here: . Subscribe to RSS Feed. INSERM - University Paris-Sud. Director: This email address is being protected from spambots. You need JavaScript enabled to view it. Deputy director: This email address is being protected from spambots. You need JavaScript enabled to view it. Faculté de Pharmacie. 5, Rue Jean-Baptiste Clément. 33)(0)1 46 83 57 57. 33)(0)1 46 83 54 75. This email address is being protected from spambots. You need JavaScript enabled to view it. Last update : January 12.
INSERM - UMR866 - Centre de recherche - Accueil
Préparation d'un gel de protéine, dépôt des échantillons avant électrophorèse. Coloration au bleu de Coomassie de protéines recombinantes après électrophorèse. Immunomarquage de protéines après électrophorèse. Observation microscopique de cellules en culture. Plaques et boites de culture cellulaire. INSERM UMR1037, Cancer Research Center of Toulouse. Tumor Necrosis Factorα blockade overcomes resistance to anti-Programmed-cell Death-1 in experimental melanoma. Fac Sciences Gabriel - Amphi Billet 14h30.
| Inserm - La science pour la santé
Aller au contenu principal. Professionnels de la recherche. L’Inserm en un coup d’œil. Implantation des structures de recherche. Double cursus médecine /science. Yves Lévy dresse la feuille de route 2018 de l’Inserm. La recherche à l'Inserm. Le continuum de la recherche. La recherche en santé publique. La valorisation et le transfert des découvertes. Caroline Goujon déniche des antiviraux endogènes. Reportage en labo : L'immunologie à toutes les échelles. Médecine/sciences n 3 vol.34. Big data en santé.
Institut national de la santé et de la recherche médicale
Forces de la recherche. Neurosciences, sciences cognitives, neurologie, psychiatrie. Rêves de recherche, rêve de chercheurs. Les acteurs de la recherche sur le cancer. Recherche sur les cancers : tout s’accélère (web documentaire). Rêves de recherche, rêve de chercheurs. Immunologie, inflammation, infectiologie et microbiologie. Enjeux scientifiques et médicaux. Rêves de recherche, rêve de chercheurs. Physiopathologie, métabolisme, nutrition. Rêves de recherche, rêve de chercheurs. Faire un don ou un legs.
